Read more

June 24, 2022
1 min read
Save

Top in GI: Pediatric hepatitis; colorectal cancer screening barriers

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CDC researchers said they did not find a recent increase in cases of hepatitis or adenovirus types 40/41 among children in the United States compared with pre-pandemic baseline levels.

The analysis was conducted after the CDC received reports of pediatric hepatitis cases of unknown etiology, many of which had also tested positive for adenovirus. Although the researchers found no significant increase in pediatric hepatitis or adenovirus types 40/41, they said the data do not infer or disprove a causal association between the two illnesses. It was the top story in gastroenterology last week.

HGI0622MMWR_Graphic_01
Source: Adobe Stock

The second top story was about new evidence-based statements from the American Gastroenterological Association that aim to improve colorectal cancer screening. The statements highlight the importance of accessibility and eliminating factors that may contribute to socioeconomic disparities.

Read these and more top stories in gastroenterology below:

Data suggest no increase in pediatric hepatitis, adenovirus above pre-pandemic levels

Data reported in Morbidity and Mortality Weekly Report did not demonstrate an increase in pediatric hepatitis or adenovirus types 40/41 above pre-COVID-19 pandemic baseline levels. Read more.

AGA releases position statements to improve CRC screening, eliminate existing barriers

The AGA has released a series of evidence-based position statements that support a nationwide colorectal cancer screening approach and aim to eliminate current barriers in the screening process. Read more.

FDA approves Skyrizi for moderately to severely active Crohn's disease

The FDA has approved Skyrizi (risankizumab-rzaa, AbbVie) for the treatment of adults with moderately to severely active Crohn’s disease, according to a company press release. Read more.

VIDEO: Patients with celiac disease report greater dating hesitancy, social anxiety

In this video, Jessica Lebovits, RD, CDN, discusses research that revealed many patients with celiac disease experience negative effects on their dating life, resulting in less adaptive eating attitudes and decreased quality of life. Read more.

Emergence of digital therapeutics boosts access to GI behavioral resources

As the field of gastroenterology evolves, gone are the days when a gastroenterologist is expected to meet the needs of every patient. Research has shown the benefits of tailoring a patient’s treatment team to include a GI psychologist, registered GI dietitian, pelvic floor therapist and more. Read more.